Effect of Short-term Application of Atorvastatin Combined with Ezetimibe on Lipid-lowering Efficacy and Related Indicators of Patients with Nephrotic Syndrome with Hyperlipidemia
10.6039/j.issn.1001-0408.2017.06.15
- VernacularTitle:短期应用阿托伐他汀联合依折麦布对原发性肾病综合征合并高脂血症患者降脂疗效及相关指标的影响
- Author:
Yaoyue TAN
;
Jun LIU
;
Ze LI
;
Juan WANG
;
Guobing SHI
;
Dewei ZHANG
;
Dasheng DANG
- Keywords:
Nephrotic syndrome;
Ezetimibe;
Atorvastatin;
Hyperlipidemia;
Efficacy
- From:
China Pharmacy
2017;28(6):773-776
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To explore the effects of short-term application of atorvastatin combined with ezetimibe on efficacy and related indicators of patients with primary nephrotic syndrome with hyperlipidemia. METHODS:Data of 50 patients with prima-ry nephrotic syndrome with hyperlipidemia were retrospectively collected and divided into combination group and control group ac-cording different treatment,25 cases in each group. All patients received low-salt,low-fat ,high-quality protein,giving prednisone 1 mg/(kg·d),po,qd,combined with anticoagulation,diuretic,anti-infection,taking cytotoxic drugs if necessary. Based on it, control group received Atorvastatin calcium tablet 20 mg before going to bed,qd;combination group received Atorvastatin calcium tablet(the same dosage and usage with control group)+Ezetimibe tablet 10 mg,qd. They were treated for 2 weeks. Lipid-lowering efficacy and low-density lipoprotein(LDL-C),triglyceride(TG),cholesterol(TC),high-density lipoprotein(HDL-C),24 h uri-nary protein (M-TP),serum albumin,alanine aminotransferase (ALT),aspartate aminotransferase (AST),serum creatinine and blood urea nitrogen before and after treatment in 2 groups were observed and the incidence of adverse reaction was recorded. RE-SULTS:There was no significant differences in the total effective rate of Lipid-lowering in 2 groups(P>0.05). After treatment, LDL-C,TC and HDL-C in 2 groups were significantly lower than before,Alb in combination group and ALT in 2 groups were sig-nificantly higher than before,with statistical significance(P<0.05),while there were no significant difference in 2 groups(P>0.05). And there was no significant difference in the TG,M-TP,AST,serum creatinine and blood urea nitrogen before and after treatment(P>0.05). CONCLUSIONS:Atorvastatin combined with ezetimibe can improve the blood lipid of patients with primary nephrotic syndrome with hyperlipidemia,while showing similar efficacy and safety with atorvastatin alone in a short term.
